Status:
COMPLETED
Effect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia Adults
Lead Sponsor:
Pusan National University Yangsan Hospital
Conditions:
Muscular Sarcoidosis
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Nelutri™on muscle strength, muscle mass, and muscle function in healthy adults for 12 weeks...
Detailed Description
A previous study has indicated that Nelutri™ may increase muscle mass and strength. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects...
Eligibility Criteria
Inclusion
- \<110% of the standard lean body mass as measured using the body composition analyzer
- Body-mass index (BMI) ranging from 18.5 to 30.0 kg/m2
- Those who have an average protein intake of 60 g or more/day.
Exclusion
- Abnormal liver or renal function (i.e., serum aminotransferase activity \> 60 IU/L and serum creatinine concentrations \> 1.2 mg/dL)
- Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL)
- History of fracture during the previous year
- Uncontrolled hypertension
- History of serious cardiac disease such as angina or myocardial infarction
- History of gastrectomy
- History of medication for psychiatric disease
- Administration of oriental medicine including herbs within the past 4 weeks
- Evidence of relatively high skeletal mass (more than 110% of the standard lean body mass as measured using the body composition analyzer
Key Trial Info
Start Date :
March 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04320121
Start Date
March 11 2020
End Date
December 31 2020
Last Update
April 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Yangsan Hospital
Yangsan, Gyeungsangnam-do, South Korea, 50612